Format

Send to

Choose Destination
Vaccine. 2015 Jan 3;33(2):346-53. doi: 10.1016/j.vaccine.2014.11.016. Epub 2014 Nov 21.

Evaluation of the immune response and protective efficacy of Schistosoma mansoni Cathepsin B in mice using CpG dinucleotides as adjuvant.

Author information

1
Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada; National Reference Center for Parasitology, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.
2
Institute of Parasitology, McGill University, Montreal, Quebec, Canada; School of Biological Sciences, Medical Biology Centre (MBC), Queen's University Belfast, Ireland.
3
Department of Microbiology & Immunology, McGill University, Montreal, Quebec, Canada; National Reference Center for Parasitology, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada. Electronic address: momar.ndao@mcgill.ca.

Abstract

Schistosomiasis is the most important human helminth infection due to its impact on public health. Worldwide, schistosomiasis is estimated to infect at least 200 million individuals while 700 million are at risk. The clinical manifestations are chronic and significantly decrease an individual's quality of life. Infected individuals suffer from long-term organ pathologies including fibrosis which eventually leads to organ failure. The development of a vaccine against this parasitic disease would contribute to a long-lasting decrease in disease spectrum and transmission. Our group has chosen to target Schistosoma mansoni Cathepsin B as a prospective vaccine candidate. The recombinant protein was tested in the presence of synthetic oligodeoxynucleotides containing unmethylated CpG dinucleotides, which are Toll-like receptor 9 agonists known to stimulate a Th1 response. This formulation conferred a 59% decrease in worm burden as well as a reduction in egg burden. Hepatic egg burden and intestinal egg burden were decreased by 56% and 54% respectively. Immunizations with the formulation elicited robust production of Sm-Cathepsin B specific antibodies, both IgG1 and IgG2c but with the latter predominating. Furthermore, splenocytes isolated from the immunized animals, compared to control animals, had increased secretion levels of key Th1 cytokines, IFN-γ and TNF-α, as well as the chemokine CCL5 when stimulated with recombinant Sm-Cathepsin B. These results highlight the potential of Sm-Cathepsin B/CpG as a vaccine candidate against schistosomiasis.

KEYWORDS:

Antigen-specific antibodies; Cathepsin B; CpG dinucleotides; Cytokine production; Schistosomiasis; Vaccine

PMID:
25448114
DOI:
10.1016/j.vaccine.2014.11.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center